- High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma
Ádám Széles et al, 2022, Biomedicines CrossRef - High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy
Ulrich Krafft et al, 2021, Cancers CrossRef - Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Kaijian Zhou et al, 2020, Frontiers in Cell and Developmental Biology CrossRef - Clinical Progress of PD-1/PD-L1 Small Molecule Inhibitors
帆 杨, 2024, Hans Journal of Medicinal Chemistry CrossRef - Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu et al, 2022, Frontiers in Immunology CrossRef - Elevated Plasma Soluble PD-L1 Levels in Out-of-Hospital Cardiac Arrest Patients
Miho Sumiyoshi et al, 2021, Journal of Clinical Medicine CrossRef - Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma
Christopher M. Black et al, 2024, Frontiers in Oncology CrossRef - Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly et al, 2021, Cancers CrossRef - Methylseleninic Acid Sensitizes Ovarian Cancer Cells to T-Cell Mediated Killing by Decreasing PDL1 and VEGF Levels
Deepika Nair et al, 2018, Frontiers in Oncology CrossRef - Erzhi pills reverse PD-L1-mediated immunosuppression in melanoma microenvironment
Zhirui Fang et al, 2024, Heliyon CrossRef - CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
Markus Zeisbrich et al, 2021, Frontiers in Immunology CrossRef - Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma
Petra Terézia Kovács et al, 2022, Biomedicines CrossRef - Prognostic impact of soluble PD-L1 derived from tumor-associated macrophages in non-small-cell lung cancer
Koji Teramoto et al, 2023, Cancer Immunology, Immunotherapy CrossRef